
The US congress is again subjecting the pharmaceutical industry to heavy scrutiny over drug pricing policies with Mylan its latest …

Valeant (NYSE: VRX) has announced the establishment of a new patient access and pricing committee that will be responsible for …

Valeant have hit the mainstream news again after key investor Bill Ackman mounted a robust defence of the company, ruling …

Price gouging has become synonymous with drug costs in the US, with the infamous Martin Shkreli and troubled Valeant becoming …
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
How will biomarker-led diagnostics reshape respiratory medicine?

